More from the company

Published: 2017-02-03 08:30:05

WntResearch AB: WntResearch and the University of Copenhagen to investigate potential interaction between Foxy-5 and cancer immunotherapy

WntResearch’s leading drug candidate Foxy-5 has in an ongoing clinical study shown a biological effect in cancer patients. The company will now commence a collaboration with Associate Professor Peter Holst at the Department of Immunology and Microbiology at the University of Copenhagen, in order to investigate if and how Foxy-5 can be combined with immunotherapies in treating cancer.

”If Foxy-5 – besides its anti-metastatic qualities – can be combined and function well together with new immunotherapies, further interesting possibilities open up for the drug candidate to become a key component in treating cancer in the future” says Henrik Lawaetz, CEO, WntResearch AB.

The aim of the collaboration, which is based on pre-clinical experimental models, is to increase the knowledge base about important immunological factors connected to metastasis and how Foxy-5 can affect these factors.

For further information contact:

Henrik Lawaetz, CEO
Telephone: +46 72 702 4694

The information was submitted for publication, through the agency of the contact person set out above, at 8.30 CET on February 3, 2017.

About WntResearch

WntResearch is developing a new type of cancer treatment based on pioneering research, which shows that the endogenous protein Wnt-5a plays a crucial role for tumour cells’ ability to relocate and spread inside the body. Most patients that die of cancer do so not due to the primary tumour, but due to metastasises and the need for a specific treatment to counteract metastasis is therefore in high demand.

WntResearch’s most advanced drug candidate Foxy-5 has in preclinical tests been shown to reduce tumour cells’ mobility and thereby counteract the occurrence of metastasis. The results from a completed phase 1 study show a favourable security profile and pharmacokinetics as well as early indications of biological activity. A phase 1b study is currently ongoing in patients with cancer in colon, prostate and breast. WntResearch is a public company listed at AktieTorget in Stockholm, Sweden. For further information:

Läs mer hos Cision
Read more about WntResearch AB